Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector




















Sort by: Date|Relevance

Buzz on the Bullboards: On the verge of recession? These stocks could be a lifesaver

Welcome back to Buzz on the Bullboards. It has been a busy week for markets and investors alike. Each new twist has sent currencies and commodities bouncing up and down, and no one can figure out...

Fintech Payment Solutions Provided…Seamlessly

In mid-July , our Stockhouse audience was introduced to a fintech company with a very unique business model that’s created a secure, easy-to-use payment solution for the student market – Euro Asia Pay Holdings Inc. (EAP) ( CSE.EAP , Forum ). St...

Regeneron Reports Positive Phase 3 Dupixent Data; Gains EU Approval Recommendation

Regeneron Pharmaceuticals published positive results from two U.S. Phase 3 trials evaluating the safety and efficacy of Dupixent (dupilumab) in adults with recurring severe chronic rhinosinusitis with nasal polyps. The European Medicines Agency's Committee for Medicinal Produc...

Intra-Cellular Therapies Shares Rise 200% on FDA Approval of Adult Schizophrenia Drug

Shares of Intra-Cellular Therapies opened greater than 100% higher today after the company reported that the FDA approved its antipsychotic CAPLYTA® (lumateperone) drug for the treatment of schizophrenia in adults. This morning a biopharmaceutical company foc...

Could the coronavirus cause the next ‘Arab Spring’?

The rich are getting richer, inequality is on the rise, and the middle class, the backbone of the US economy since the 1950s, is shrinking. In 2018 the three highest-paid chief executives in the United States earned more than the output of several countries. Tesla&Close...

Significant Size, Grade, Returns

Steve Todoruk of Sprott USA , and the 2019 Pezim Award winner sits down with Maurice Jackson of Proven and Probable to discuss the Significant New Discoveries and the impact on your portfolio. Mr. Todoruk has a proven pedigree of identifying promising new...

RedHill Biopharma Shares Rise 10% After Receiving FDA Approval for H. Pylori Treatment Drug Talicia

Shares of RedHill Biopharma Ltd. traded more than 10% higher today after the firm announced that the FDA has approved its Talicia delayed-release capsules for the treatment of H. pylori infection in adults. The firm plans to commence distribution by its U.S. sales force in Q1/...

Dec 12th 2019, Silver Chartbook – Aggressive participation, why?

Aggressive participation, why? As much as we use a technical analysis dominated approach toward the markets, it would be foolish to not have those views guided by fundamentals. It is at this point in time a true confluence point of world wide events that drive o...

Ovid Therapeutics Posts Positive Data from Phase 2 Seizure Reduction Trial

Ovid Therapeutics' shares are trading 25% higher today after the company reported positive initial data from its ENDYMION soticlestat phase 2 trial for patients with developmental and epileptic encephalopathies. Shares of Ovid Therapeutics Inc. (OVID:NASDAQ) are tra...

Aphria, Canopy Growth, EXMceuticals - Europe becomes the largest cannabis market

The consulting firm Prohibition Partners expects Europe to grow into the world's largest market for legal cannabis products in the next five years. Germany will become by far the largest market for medical cannabis products. According to the experts, Europe will thus overtake ...
1 2 3 4 5 6 7 8 9 10 ...